Canadian Halal Investor.

NASDAQ Shariah screener · October 2026

Is Twist Bioscience Corporation (TWST) Halal?

PASS

Twist Bioscience Corporation · NASDAQ: TWST · Healthcare

The short answer

Twist Bioscience passes all three Shariah gates: it builds synthetic-DNA tools for research and drug discovery (not an interest-based lender), carries no interest-bearing debt (0.0% of its ~$12.23 billion market cap), and interest income of about 3.02% of revenue is under the 5% ceiling.

Gate 1 — Business activity: PASS

Gate 1 — business activity: PASS. Twist Bioscience Corporation, per its FY2025 Form 10-K (fiscal year ended September 30, 2025, filed November 2025), is a biotechnology company headquartered in South San Francisco, California (founded 2013, NASDAQ-listed since 2018). It develops and manufactures synthetic DNA using a proprietary silicon-based DNA synthesis platform: synthetic genes, oligonucleotide pools, next-generation sequencing sample-preparation tools, and antibody libraries for drug discovery and development, serving life sciences, agricultural, industrial chemical, and DNA data storage markets. FY2025 revenue was $376.6 million, up 20.3% year over year.

It is not an interest-based lender and is not involved in tobacco, gambling, pork, or conventional banking or insurance. Its FY2025 net loss of $77.7 million reflects R&D investment typical of a commercial-stage biotech, not a haram business line. The business passes gate 1.

Gate 2 — Debt and cash: PASS

Gate 2 — interest-bearing debt: PASS (0.0%, ceiling 33%). Per Twist Bioscience's FY2025 consolidated balance sheet (September 30, 2025, Form 10-K), the company carries no interest-bearing debt — long-term borrowings are zero and total debt is $0.00 (only $62 million of finance lease obligations, which are not interest-bearing debt).

$0 against a market capitalization of about $12.23 billion (Finnhub, October 2, 2026) is about 0.0%, under the 33% ceiling. Cash and cash equivalents of about $183 million at September 30, 2025 represent about 1.5% of market capitalization.

Gate 3 — Non-compliant income: PASS

Gate 3 — non-compliant income: PASS (3.02%, ceiling 5%). Twist Bioscience's FY2025 Form 10-K separately discloses interest income on its own income-statement line: $11,364 thousand of interest income against revenue of $376,572 thousand is about 3.02% — under the 5% ceiling (fiscal 2024: $15,344 thousand of $312,974 thousand, about 4.90%, also under the ceiling). The most recent annual figure (3.02%) is used for this gate.

Key figures used

Frequently asked questions

What does Twist Bioscience do?

Twist Bioscience Corporation (NASDAQ: TWST) is a biotechnology company headquartered in South San Francisco, California, founded in 2013 and listed on NASDAQ since 2018. Per its FY2025 Form 10-K (fiscal year ended September 30, 2025, filed November 2025), it develops and manufactures synthetic DNA using a proprietary silicon-based DNA synthesis platform, selling synthetic genes, oligonucleotide pools, tools for next-generation sequencing sample preparation, and antibody libraries for drug discovery and development. Its products serve life sciences, agricultural, industrial chemical, and DNA data storage markets. FY2025 revenue was $376.6 million, up 20.3% year over year.

Is Twist Bioscience's business Shariah compliant?

Twist Bioscience develops and manufactures synthetic DNA and synthetic-biology tools for research and drug discovery - it is not an interest-based lender and is not involved in tobacco, gambling, pork, or conventional banking or insurance. Its operating losses ($77.7 million net loss in FY2025) reflect R&D investment typical of a commercial-stage biotech, not a haram business line. Assessed on the filed numbers, the business passes this screener's first gate.

How much interest-bearing debt does Twist Bioscience have?

Twist Bioscience's FY2025 balance sheet (September 30, 2025) reports no interest-bearing debt - long-term borrowings are zero and total debt is $0.00 (only $62 million of finance lease obligations, which are not interest-bearing debt). Against a market capitalization of about $12.23 billion (Finnhub, October 2, 2026), that is about 0.0% - under the 33% ceiling. Cash and cash equivalents of about $183 million at September 30, 2025 represent about 1.5% of market capitalization.

How much interest income does Twist Bioscience earn?

Twist Bioscience's FY2025 Form 10-K separately discloses interest income on its own income-statement line: interest income of $11,364 thousand against revenue of $376,572 thousand is about 3.02% - under the 5% non-compliant income ceiling (fiscal 2024: $15,344 thousand of $312,974 thousand, about 4.90%, also under the ceiling). The most recent annual figure (3.02%) is used for this gate.

What do third-party Shariah screeners say about Twist Bioscience?

Zoya publishes a TWST page citing fiscal 2025 figures ($376,572,000 revenue, $11,364,000 interest income, 3.02%) under its AAOIFI methodology, and its September 2026 update indicates Shariah-compliant. MuslimXchange also publishes a TWST compliance page (updated September 10, 2026) indicating Shariah compliant across its standards. I could not verify a Musaffa rating page for TWST or a ShariaPortfolio rating from public sources. Third-party screeners apply different assumptions and update on different schedules, and their results can change when new financial statements are published - always check the latest screening before investing.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).